echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Under the high barrier of anesthetics, the domestic imitated drugs catch up with the original drugs

    Under the high barrier of anesthetics, the domestic imitated drugs catch up with the original drugs

    • Last Update: 2013-12-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: medical economics report December 12, 2013 anesthesia is a crucial link in surgery The quality of anesthesia is directly related to the success or failure of surgery, and also to a certain extent determines the safety of patients Compared with other sub industries in the pharmaceutical industry, the anesthesia industry has some special industry attributes The clinical promotion of narcotic drugs is very professional, doctors need to prescribe according to the established scheme, which also leads to many new enterprises in the industry are difficult to make a difference From the perspective of the overall market, it is dominated by foreign enterprises and influential domestic enterprises Because of its strong specialty and high barriers, the competition pattern is relatively stable, the whole industry is in a state of oligopoly, and relatively maintains a high growth level of the whole industry The most popular anesthetics and auxiliary drugs in the world are lidocaine, sevoflurane and propofol In 2011, sales of the three major products were $830 million, $790 million and $290 million, respectively In 2004, sales of sevoflurane and propofol reached a peak of US $1.16 billion and US $500 million respectively After 2004, sales of sevoflurane and propofol decreased steadily The sales volume of lidocaine in 2003 was US $180 million, reaching US $710 million in 2007, but the sales growth after 2007 was slightly calm Anesthetics are widely used in clinical practice in China With the increasing number of domestic operations, the sales volume of anesthetics is also expanding The fast-growing market and relatively stable competitive environment are favored by major pharmaceutical companies Domestic enterprises have taken anesthetics as an important direction in strategic development According to the data of 22 sample hospitals in China, in 2012, the sales volume of anesthesia and auxiliary drugs reached 1.92 billion yuan, a year-on-year increase of 17.9%; the compound growth rate of drug purchase amount from 2005 to 2012 was 25.4%, higher than the average value of the whole drug industry In addition, the proportion of sales and purchase amount of narcotic and auxiliary drugs in total drugs increased year by year, from 393 million yuan in sales in 2005, 1.2% in the overall market, to 1.915 billion yuan in sales in 2012, 1.7% in the overall market On the whole, the competitiveness of domestic generic drugs is strong, and the market share of many original research products is lower than that of generic products At present, there are more than 150 domestic enterprises involved in narcotic drugs and auxiliary drugs In terms of sales volume in 2012, foreign-funded enterprises accounted for 52.8%, while domestic enterprises accounted for 47.2% Among them, the top 10 enterprises have 81.8% market share In terms of treatment categories, general anesthetics accounted for 69.1%, muscle relaxants 22.4% and local anesthetics 8.5% The top five companies with outstanding performance are: AstraZeneca pharmaceutical, with sales of 420 million yuan; Jiangsu Hengrui pharmaceutical, with sales of 330 million yuan; Wuhan humanwell Pharmaceutical Co., Ltd., with sales of 250 million yuan; feisenyuskabi, with sales of 160 million yuan; marushi Pharmaceutical Co., Ltd., with sales of 150 million yuan The market share of the top five enterprises was 21.9%, 17.1%, 13.0%, 11.8% and 8.5% respectively; the growth rate in 2012 was 11.5%, 29.5%, 28.6%, 44.9% and 1.0% respectively compared with the same period in 2011 The market concentration of anesthetics in China is quite high, and the marketing channels are mainly controlled by several large enterprises It is difficult for other enterprises to enter the market of anesthetics According to the data of 22 sample hospitals in China, in 2012, AstraZeneca ranked the leading position by virtue of propofol, an intravenous anesthetic; Hengrui pharmaceutical, a domestic enterprise, ranked second by virtue of sevoflurane and atracurium; Wuhan humanwell Pharmaceutical Co., Ltd., Hubei Province, ranked third by virtue of remifentanil and sufentanil Anesthesia industry is in the pattern of oligopoly, which is not due to the policy The main reason lies in the professional barriers, strict monitoring by the state, low industry competition, and the above-mentioned enterprises in the industry occupy the market first mover advantage The future growth of anesthetics is mainly driven by the growth of surgery volume, the expansion of drug use field and the upgrading of products Therefore, there is still a huge development space in the market According to the data of 22 sample hospitals in China, the total number of products involving anesthetics and their auxiliary drugs is 35 In terms of sales in 2012, the top 10 products accounted for 94.8%, while the other 25 products only accounted for 5.2% It can be seen that the top ten products of anesthetics and their auxiliary drugs have a high market concentration Anesthesia methods are divided into general anesthesia, half body anesthesia and regional anesthesia Different anesthesia methods are used in different operations Although the volume of general anesthesia is far less than that of local anesthesia, but its price is relatively expensive, so general anesthesia occupies an absolute advantage in the national anesthesia market share, while local anesthesia occupies a small share In 2012, the top 10 products in the sales volume of anesthetics in sample hospitals were propofol, sevoflurane, atracurium, remifentanil, sufentanil, ropivacaine, rocuronium, etomidate, vecuronium and compound lidocaine Among them, there are 5 general anesthetics with a total sales volume of 1.31 billion yuan, accounting for 72.0% of the top 10 products There are three muscle relaxants with a total sales volume of 420 million yuan, accounting for 23.1% of the top 10 products There are two local anesthetics, with a total sales volume of 88.91 million yuan, accounting for 4.9% of the top 10 products Propofol imported strong propofol is a short effect intravenous general anesthesia drug, which is widely used in clinical anesthesia operation with the advantages of quick onset and rapid recovery The drug has been listed in the catalogue of essential drugs in China In 2012, the sales of this variety reached 650 million yuan, an increase of 17.5% over the same period According to the sales trend of 2005-2012, the annual compound growth rate is 20.3% At present, domestic propofol is monopolized by import enterprises In 2012, the sales volume of AstraZeneca and freseniuskabi propofol was 420 million yuan and 160 million yuan respectively, accounting for 64.0% and 25.0% market shares respectively The market share of Xi'an Libang Pharmaceutical Co., Ltd and Sichuan Shule Pharmaceutical Co., Ltd is very small, accounting for only 11.0% Sevoflurane rapid growth sevoflurane is a relatively new inhalation general anesthesia drug, developed by Abbott pharmaceutical company, approved by FDA in 1995, and entered China in 1996 In 2012, the amount of drug used in sample hospitals was 340 million yuan, an increase of 8.2% over the same period From the perspective of sales trend in 2005-2012, the annual compound growth rate is 93.6%, with a rapid growth rate At present, the market share gap between domestic sevoflurane import and domestic enterprises is not large In 2012, the drug amount of marushi pharmaceutical in Japan and Hengrui pharmaceutical in Jiangsu was 150 million yuan and 130 million yuan respectively, accounting for 46.0% and 39.0% respectively Atracurium has a good competitive pattern Atracurium is a muscle relaxant and an auxiliary anesthetic In 2012, the amount of drug used in sample hospitals was 330 million yuan, an increase of 27.0% over the same period According to the sales trend of 2005-2012, the annual compound growth rate is 57.0% At present, the domestic atracurium market is mainly occupied by Jiangsu Hengrui pharmaceutical and Dongying (Jiangsu) pharmaceutical industry, with sales of 190 million yuan and 110 million yuan respectively in 2012, accounting for 56.2% and 31.8% shares Atracurium is only produced by Hengrui, Dongying (Jiangsu) Pharmaceutical Co., Ltd., Xianju Pharmaceutical Co., Ltd and Glaxo, the original research enterprise in China, with fewer manufacturers and a good market competition pattern In recent years, atracurium has maintained a relatively rapid growth trend, and the growth trend continues.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.